Ivermectin Versus Albendazole for Chronic Strongyloidiasis
NCT ID: NCT00765024
Last Updated: 2017-09-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
90 participants
INTERVENTIONAL
2008-07-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis
NCT01570504
Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms
NCT05124691
Efficacy and Safety of IVM/ALB Co-administration
NCT03527732
Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
NCT06184399
Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
NCT06070116
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Albendazole
Albendazole for 7 days
Albendazole
Albendazole 7 days
ivermectin
ivermectin 200 mcg/kg single dose
Ivermectin
single dose of 200 mcg/kg
ivermectin 2 doses
ivermectin 200 mcg/kg two doses in 2 weeks
ivermectin
two single dose of 200mcg/kg in 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ivermectin
single dose of 200 mcg/kg
ivermectin
two single dose of 200mcg/kg in 2 weeks
Albendazole
Albendazole 7 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Lactating women
* Known allergy to any study drug
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Atlantic Laboratory Ltd
UNKNOWN
Mahidol University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yupin Suputtamongkol, MD
Role: PRINCIPAL_INVESTIGATOR
Mahidol University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Siriraj Hospital
Bangkoknoi, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Suputtamongkol Y, Premasathian N, Bhumimuang K, Waywa D, Nilganuwong S, Karuphong E, Anekthananon T, Wanachiwanawin D, Silpasakorn S. Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. PLoS Negl Trop Dis. 2011 May 10;5(5):e1044. doi: 10.1371/journal.pntd.0001044.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TM001-2008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.